Inhibikase Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Inhibikase Therapeutics has a total shareholder equity of $11.0M and total debt of $381.8K, which brings its debt-to-equity ratio to 3.5%. Its total assets and total liabilities are $14.5M and $3.5M respectively.
Key information
3.5%
Debt to equity ratio
US$381.78k
Debt
Interest coverage ratio | n/a |
Cash | US$13.25m |
Equity | US$10.98m |
Total liabilities | US$3.53m |
Total assets | US$14.51m |
Recent financial health updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Inhibikase Therapeutics prices stock offering at $3
Jun 16Financial Position Analysis
Short Term Liabilities: IKT's short term assets ($14.2M) exceed its short term liabilities ($3.4M).
Long Term Liabilities: IKT's short term assets ($14.2M) exceed its long term liabilities ($90.1K).
Debt to Equity History and Analysis
Debt Level: IKT has more cash than its total debt.
Reducing Debt: IKT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IKT has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: IKT is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.